Navigation Links
Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
Date:10/6/2009

NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile

http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Gilead's performance against key rivals in the prescription pharmaceutical sector

*See how Gilead's HIV franchise will drive continued double-digit sales growth for the company out to 2014

*Assess the impact of the company's recently announced collaboration with Tibotec for a 'second generation Atripla'

TABLE OF CONTENTS

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Data sourcing 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Gilead Sciences: PharmaVitae forecasts at a glance 8

Strategic insight 9

SWOT analysis 16

Chapter 3 Quarterly news update 24

Product developments 24

Deals and alliances 25

M&A activity 27

Company announcements 28

Future product milestones 29

Chapter 4 Company introduction 30

Key findings 30

Background 31

Key corporate developments 31

M&A history 31

Chapter 5 Company sales 34

Key findings 34

Prescription pharmaceutical sales and growth rate analysis, 2002-14 35

Product analysis 37

Therapy area analysis 44

Geographic analysis 46

Launch/core/expiry analysis 49

Molecule type analysis 54

Externalization analysis 56

Chapter 6 Company financials 59

Key findings 59

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 60

Operating costs and profit analysis 61

Chapter 7 Key products and competitors 67

Key findings 67

Overview 68

Infectious diseases 69

Cardiovascular 80

Chapter 8 Appendix 83

R&D pipeline 83

References 84

Abbreviations 84

About Datamonitor 86

Datamonitor consulting 86

Disclaimer 88

Table of tablesTable 1: Gilead - PharmaVitae forecasts at a glance 8

Table 2: Gilead's HIV franchise, 2008-14 ($m) 10

Table 3: Gilead key product developments, 2009 24

Table 4: Gilead product deals and alliances, 2009 25

Table 5: Gilead technology deals and alliances, 2009 26

Table 6: Gilead M&A activity, 2009 27

Table 7: Gilead company announcements, 2009 28

Table 8: Gilead future product milestones, 2009-11 29

Table 9: Gilead product portfolio overview ($m), 2002-08 39

Table 10: Gilead product portfolio overview ($m), 2008-14 41

Table 11: Gilead prescription pharmaceutical sales by therapy area ($m), 2008-14 45

Table 12: Gilead prescription pharmaceutical sales by geographic region ($m), 2008-14 48

Table 13: Gilead launch portfolio overview ($m), 2008-14 50

Table 14: Gilead core portfolio overview ($m), 2008-14 51

Table 15: Gilead expiry portfolio overview ($m), 2008-14 52

Table 16: Gilead prescription pharmaceutical sales by molecule type ($m), 2008-14 55

Table 17: Gilead prescription pharmaceutical sales by source ($m), 2008-14 57

Table 18: Total Gilead sales by business unit ($m), 2002-08 60

Table 19: Gilead operating revenue/cost analysis ($m), 2002-08 62

Table 20: Gilead operating cost ratio analysis (% of total revenues), 2002-08 63

Table 21: Gilead operating cost ratio analysis (% of total revenues), 2008-14 64

Table 22: Gilead operating revenue/cost analysis ($m), 2008-14 65

Table 23: Key products overview 68

Table 24: Atripla: overview 69

Table 25: Atripla: sales forecast ($m), 2008-14 70

Table 26: Truvada: overview 72

Table 27: Truvada: sales forecast ($m), 2008-14 73

Table 28: Viread: overview 75

Table 29: Viread: sales forecast ($m), 2008-14 76

Table 30: Truvada + rilpivirine: overview 78

Table 31: Truvada + rilpivirine: sales forecast ($m), 2008-14 79

Table 32: Letairis: overview 80

Table 33: Letairis: sales forecast ($m), 2008-14 81

Table 34: Gilead Sciences R&D pipeline (Phase I-registration) 83

TABLE OF FIGURES

Figure 1: The PharmaVitae Explorer 3

Figure 2: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Gilead's financial performance ($m), 2002-14 7

Figure 4: Sales of the leading HIV therapy players, 2002-14 ($m) 12

Figure 5: Gilead prescription pharmaceutical sales by source, and therapy area ($m), 2002-14 14

Figure 6: Gilead SWOT analysis 16

Figure 7: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 35

Figure 8: Key product sales ($m), 2002-14 38

Figure 9: Gilead key sales growth drivers and resistors ($m), 2002-08 40

Figure 10: Gilead key sales growth drivers and resistors ($m), 2008-14 42

Figure 11: Gilead prescription pharmaceutical sales by therapy area ($m), 2002-14 44

Figure 12: Gilead prescription pharmaceutical sales by geographic region ($m), 2002-14 47

Figure 13: Gilead launch/core/expiry configuration ($m), 2008-14 53

Figure 14: Gilead prescription pharmaceutical sales by molecule type ($m), 2002-14 54

Figure 15: Gilead prescription pharmaceutical sales by source ($m), 2002-14 56

Figure 16: Gilead operating revenue/cost analysis ($m), 2002-14 61

To order this report:

Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile

http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
3. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
4. Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
5. PARIs eFlow Included in Gileads NDA Submission for Aztreonam Lysine for Inhalation
6. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
7. New Momentum Teams With Oracle to Help Reduce Counterfeiting in the Life Sciences Industry
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Life Sciences Company Opens Clinical Trial Bridge to India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):